MGO One Seven LLC Has $329,000 Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

MGO One Seven LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 989 shares of the company’s stock after acquiring an additional 203 shares during the quarter. MGO One Seven LLC’s holdings in Medpace were worth $329,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Barclays PLC raised its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Virtu Financial LLC bought a new stake in Medpace during the third quarter worth $1,503,000. Wilmington Savings Fund Society FSB bought a new stake in Medpace during the third quarter worth $175,000. Tidal Investments LLC raised its position in Medpace by 257.9% during the third quarter. Tidal Investments LLC now owns 3,654 shares of the company’s stock worth $1,220,000 after acquiring an additional 2,633 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Medpace by 19.4% during the third quarter. Franklin Resources Inc. now owns 188,141 shares of the company’s stock worth $66,508,000 after acquiring an additional 30,530 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Mizuho dropped their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. TD Cowen lowered shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Robert W. Baird dropped their price objective on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Truist Financial dropped their price objective on shares of Medpace from $333.00 to $300.00 and set a “hold” rating on the stock in a research report on Wednesday, April 23rd. Finally, Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $349.30.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This represents a 36.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.30% of the company’s stock.

Medpace Stock Down 0.1 %

Shares of Medpace stock opened at $298.18 on Tuesday. The company has a market capitalization of $8.57 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The firm’s 50-day moving average price is $312.88 and its two-hundred day moving average price is $331.26.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the company posted $3.20 earnings per share. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.